Business
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Announced a transformational collaboration with Roche and Genentech to build and navigate maps of biology in neuroscience and an indication in
About this update from Recursion Pharmaceuticals, Inc.
[{"type":"text","content":"Announced a transformational collaboration with Roche and Genentech to build and navigate maps of biology in neuroscience and an indication in gastrointestinal oncology and to advance up to 40 novel potential medicinesExpanded our collaboration with Bayer to include the use of Recursion's OS to map and navigate biology and increased the number of potential programs in fibrosis to more than a dozenEnrolled the first patient in our Phase 2 clinical trial for CCMAdvanced our internal pipeline of potential oncology therapeutics, including programs related to CDK12, target alpha, STK11, MYC, and multiple new programsSALT LAKE CITY, March 23, 2022 /PRNewswire/ -- Recursion (Nasdaq: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2021.\n\"2021 was an exciting year for Recursion, in which we closed one of the largest biotechnology initial public offerings in history; expanded our partnership with Bayer; entered into a transformational partnership with Roche and Genentech; received Fast Track and Orphan Drug Designations from the FDA for our NF2 and FAP programs, respectively; readied several programs to initiate clinical trials; expanded our therapeutics pipeline with numerous programs in oncology; and built and began to utilize our supercomputer, BioHive1,\" said Recursion Co-Founder & CEO Chris Gibson, Ph.D. \"As we applied our mapping and navigating capabilities to explore complex biology, we discovered and advanced many new scientific and business opportunities. We are excited for 2022 as we work to transition more biology and chemistry from maps to medicines.\"\n\nSummary of Business Highlights\nClinical ProgramsCerebral cavernous malformation (CCM) (REC-994): In March 2022, we enrolled the first patient in our Phase 2 SYCAMORE clinical trial, which is a double-blind, placebo-controlled safety, tolerability and exploratory efficacy study of this drug candidate in 60 subjects with CCM.Neurofibromatosis type 2 (NF2) (REC-2282): We plan to initiate our Phase 2/3 POPLAR-NF2 clinical trial, which is a parallel group, two stage, randomized, multicenter study of this drug candidate in the second quarter of 2022.Familial adenomatous polyposis (FAP) (REC-4881): We plan to initia...